Skip to main content
SpringerLink
Log in

Pregnancy outcome in patients with stage 1a endometrial adenocarcinoma, who conservatively treated with megestrol acetate

  • Gynecologic Oncology
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Objective

The most effective treatment of well-differentiated endometrial carcinoma is surgery. The aim of this study is the evaluation of megestrol acetate on young patients with well-differentiated endometrial cancer who wish to preserve their fertility, with regard to the receptors.

Methods

16 patients were treated initially with 160 mg/d of megestrol acetate and continued with 320 mg/d for non-responsive cases. All patients followed with FD&C and hysteroscopy. The responsive patients were referred to IVF group.

Results

Response rate to hormonal therapy was 10/16 (62.5%). The mean time of responding was 7.5 months. Other six (37.5%) patients underwent total abdominal hysterectomy (TAH).

Of 10 patients who responded to hormonal therapy, one exited of the study because of her husband’s infertility. Two patients are under IVF. Three patients did not get pregnant and four patients became pregnant and finally underwent TAH.

All patients had progesterone receptors. Only one patient lacked estrogen receptors; who also responded to treatment.

Conclusion

Progestins treatment of these patients who want to have child may be useful, but close long-term follow-up is necessary. The evaluation of estrogen and progesterone receptors assay may be useful in predicting response to the treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Bakkum-Gamez JN, Gonzalez-Bosquet J, Laack NN, Mariani A, Dowdy SC (2008) Current issues in the management of endometrial cancer. Mayo Clin Proc 83(1):97–112 (review)

    Article  PubMed  Google Scholar 

  2. Ramirez PT, Frumovitz M, Bodurka DC, Sun CC, Levenback C (2004) Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol 95:133–138

    Article  PubMed  CAS  Google Scholar 

  3. Key TJ, Pike MC (1988) The dose-effect relationship between ‘unopposed’ oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial. Cancer risk Br J Cancer 57(2):205–212

    CAS  Google Scholar 

  4. Setiawan VW, Doherty JA, Shu XO, Akbari MR, Chen C, De Vivo I, Demichele A, Garcia-Closas M, Goodman MT, Haiman CA, Hankinson SE, Henderson BE, Horn-Ross PL, Lacey JV Jr, Le Marchand L, Levine DA, Liang X, Lissowska J, Lurie G, McGrath M, Narod SA, Rebbeck TR, Ursin G, Weiss NS, Xiang YB, Yang HP, Zheng W, Olson SH (2009) Two estrogen-related variants in CYP19A1 and endometrial cancer risk: a pooled analysis in the Epidemiology of Endometrial Cancer Consortium. Cancer Epidemiol Biomarkers Prev 18(1):242–247

    Article  PubMed  CAS  Google Scholar 

  5. Frumovitz M, Gershenson DM (2006) Fertility-sparing therapy for young women with endometrial cancer. Expert Rev Anticancer Ther 6:27–32

    Article  PubMed  Google Scholar 

  6. Boing C, Kimmig R (2006) Fertility-preserving treatment in young women with endometrial cancer. Gynakol Geburtshilfliche Rundsch 46:25–33

    Article  PubMed  Google Scholar 

  7. Podczaski E, Mortel R (2001) Hormonal treatment of endometrial cancer: past, present and future. Best Pract Res Clin Obstet Gynaecol 15:469–489

    Article  PubMed  CAS  Google Scholar 

  8. Yang YC, Wu CC, Chen CP, Chang CL, Wang KL (2005) Reevaluating the safety of fertility-sparing hormonal therapy for early endometrial cancer. Gynecol Oncol 99:287–293

    Article  PubMed  CAS  Google Scholar 

  9. Eftekhar Z, Izadi-Mood N, Yarandi F, Shojaei H, Rezaei Z, Mohagheghi S (2009) Efficacy of megestrol acetate (megace) in the treatment of patients with early endometrial adenocarcinoma: our experiences with 21 patients. Int J Gynecol Cancer 19(2):249–252

    Article  PubMed  Google Scholar 

  10. Kim YB, Holschneider CH, Ghosh K, Nieberg RK, Montz FJ (1997) Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature. Cancer 79:320–327

    Article  PubMed  CAS  Google Scholar 

  11. Yahata T, Fujita K, Aoki Y, Tanaka K (2006) Long-term conservative therapy for endometrial adenocarcinoma in young women. Hum Reprod 21(4):1070–1075. Epub 2005 Dec 16. PubMed PMID: 16361282

    Google Scholar 

  12. Zivanovic O, Carter J, Kauff ND, Barakat RR (2009) A review of the challenges faced in the conservative treatment of young women with endometrial carcinoma and risk of ovarian cancer. Gynecol Oncol 115(3):504–509. (Epub 2009 Sep 15)

    Google Scholar 

  13. Lai CH, Huang HJ (2006) The role of hormones for the treatment of endometrial hyperplasia and endometrial cancer. Curr Opin Obstet Gynecol 18(1):29–34

    Google Scholar 

  14. Markman M (2005) Hormonal therapy of endometrial cancer. Eur J Cancer 41(5):673–675

    Article  PubMed  CAS  Google Scholar 

  15. Ota T, Yoshida M, Kimura M, Kinoshita K (2005) Clinicopathologic study of uterine endometrial carcinoma in young women aged 40 years and younger. Int J Gynecol Cancer 15:657–662

    Article  PubMed  CAS  Google Scholar 

  16. Niwa K, Tagami K, Lian Z, Onogi K, Mori H, Tamaya T (2005) Outcome of fertility-preserving treatment in young women with endometrial carcinomas. Bjog 112:317–320

    Article  PubMed  CAS  Google Scholar 

  17. Mousavi AS, Behtash N, Karimi Zarchi M, Modarres Gilani M, Ghaemmaghami F (2007) Fertility preservation in young women with endometrial carcinoma; report of three cases. Tehran Univ Med J 65(2):82–87

    Google Scholar 

Download references

Conflicts of interest

The authors have no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Women Hospital (Mirza Koochackhan), Tehran University of Medical Sciences, Tehran, Iran

    Elham Shirali

  2. Department of Gynecology Oncology, Women Hospital (Mirza Koochackhan), Tehran University of Medical Sciences, Tehran, Iran

    Fariba Yarandi, Zahra Eftekhar & Hadi Shojaei

  3. Preventive and Community Medicine Specialist, Brain and Spinal Injury Repair Research Center, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran

    Zahra Khazaeipour

Authors
  1. Elham Shirali
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fariba Yarandi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zahra Eftekhar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hadi Shojaei
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zahra Khazaeipour
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zahra Khazaeipour.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shirali, E., Yarandi, F., Eftekhar, Z. et al. Pregnancy outcome in patients with stage 1a endometrial adenocarcinoma, who conservatively treated with megestrol acetate. Arch Gynecol Obstet 285, 791–795 (2012). https://doi.org/10.1007/s00404-011-2021-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-011-2021-8

Keywords

Search

Navigation